Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylnaltrexone bromide - Bausch Health Companies/Progenics Pharmaceuticals

Next Previous
X
Search
Drug Profile

Methylnaltrexone bromide - Bausch Health Companies/Progenics Pharmaceuticals

Alternative Names: Methyl-naltrexone hydrobromide; Methylnaltrexonium; MNTX; MNTX 302; MOA-728; MRZ 2663BR; MRZ-2663; N-methylnaltrexone bromide; Naltrexone MB; Naltrexone methobromide; Naltrexone methylbromide; Naltrexonium methiodide; ONO-3849; Quaternary ammonium naltrexone; Relistor; Relistor Oral; SLX-G1045

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Chicago
  • Developer Ono Pharmaceutical; Progenics Pharmaceuticals; Salix Pharmaceuticals
  • Class Antineoplastics; Morphine derivatives; Quaternary ammonium compounds; Small molecules; Urologics
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation
  • Discontinued Postoperative ileus; Urination disorders

Most Recent Events

  • 21 May 2021 Pooled efficacy data from all clinical trials in Constipation presented at the 46th Annual Regional Anesthesiology and Acute Pain Medicine Meeting (ASRA-2021)
  • 13 May 2021 Pooled efficacy and adverse events data from clinical trials in Constipation presented at the 46th Annual Regional Anesthesiology and Acute Pain Medicine Meeting (ASRA-2021)
  • 05 May 2021 Bausch Health Companies withdraws a phase II/III trial in Pancreatic cancer (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) prior to enrolment (NCT04083651)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top